Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bupropion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 0.84 |
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 0.84 |
| ▸ | CHRNA1 | P02708 | 5/20 | 0.84 |
| ▸ | CHRNG | P07510 | 5/20 | 0.84 |
| ▸ | CHRNB1 | P11230 | 5/20 | 0.84 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.84 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.84 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.84 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.84 |
| ▸ | CHRND | Q07001 | 5/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.84 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.84 |
| ▸ | HRH1 | P35367 | 1/20 | 0.84 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.84 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.82 |
| ▸ | BLM | P54132 | 1/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bupropion SCHEMBL1235748 | 1.00 | SLC6A3 (0.84) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL1238156 | 1.00 | SLC6A3 (0.84) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29354885 | 0.92 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL12499296 | 0.92 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL60314 | 0.92 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL30679332 | 0.92 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL300444 | 0.92 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL38777 | 0.92 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29424575 | 0.92 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL5608195 | 0.90 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0118036-A1 | Biologically active ketone derivative, preparation and use | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-09-12 | — | — | EP | claimed |
| US-9504640-B2 | Modified release formulations of a bupropion salt | VALEANT PHARMACEUTICALS LUXEMBOURG S.Á.R.L. (LU) | 2016-11-29 | — | — | US | disclosed |
| US-20150202147-A1 | Modified Release Formulations Of A Bupropion Salt | VALEANT INTERNATIONAL BERMUDA (BM) | 2015-07-23 | — | — | US | disclosed |
| US-8932628-B2 | Modified release formulations of a bupropion salt | VALEANT INTERNATIONAL BERMUDA (BM) | 2015-01-13 | — | — | US | disclosed |
| US-8354453-B2 | Bupropion hydrobromide and therapeutic applications | VALEANT INTERNATIONAL BERMUDA (BM) | 2013-01-15 | — | — | US | disclosed |
| EP-2502621-A1 | Crystalline forms of bupropion HBr | Valeant International (Barbados) SRL (BB) | 2012-09-26 | — | — | EP | disclosed |
| EP-2474308-A1 | Pharmaceutical formulations containing bupropion hydrobromide | Valeant International (Barbados) SRL (BB) | 2012-07-11 | — | — | EP | disclosed |
| US-7884136-B2 | Modified-release formulations of a bupropion salt | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2011-02-08 | — | — | US | disclosed |
| EP-1759701-B1 | Buproprion Metabolites for treating dementia and other cerebrovascular disorders | SEPRACOR INC (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20100222435-A1 | MODIFIED-RELEASE FORMULATIONS OF A BUPROPION SALT | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2010-09-02 | — | — | US | disclosed |
| EP-1051164-A1 | PHARMACOLOGICAL USES OF PURE (+) -BUPROPION | SEPRACOR, INC. (US) | 2000-11-15 | — | — | EP | disclosed |
| EP-1051167-A1 | PHARMACEUTICAL USES OF OPTICALLY PURE (-) -BUPROPION | SEPRACOR, INC. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000051546-A2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| US-6110973-A | ADMINISTERING TO HUMAN FOR WEIGHT REDUCTION OR WEIGHT CONTROL THERAPEUTICALLY EFFECTIVE AMOUNT OF (-)-BUPROPION OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, SUBSTANTIALLY FREE OF ITS (+)-STEREOISOMER | SEPRACOR (US) | 2000-08-29 | — | — | US | disclosed |
| WO-1999038499-A2 | METHODS AND COMPOSITIONS FOR AIDING IN SMOKING CESSATION AND FOR TREATING PAIN AND OTHER DISORDERS USING OPTICALLY PURE (-)-BUPROPION | SEPRACOR INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| WO-1999038502-A1 | PHARMACEUTICAL USES OF OPTICALLY PURE (+)-BUPROPION | SEPRACOR INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| WO-1999038503-A1 | PHARMACOLOGICAL USES OF OPTICALLY PURE (+)-BUPROPION | SEPRACOR INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| WO-1999038504-A1 | PHARMACEUTICAL USES OF OPTICALLY PURE (-)-BUPROPION | SEPRACOR INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| EP-0118036-A1 | Biologically active ketone derivative, preparation and use | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-09-12 | — | — | EP | disclosed |
| EP-0118036-A1 | Biologically active ketone derivative, preparation and use | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202147-A1 | Modified Release Formulations Of A Bupropion Salt | SLC6A2, SLC6A3, SLC6A11 | SLC6A3 2/4885SLC6A2 1/4885CHRNA1 308/4885 |
| US-20100222435-A1 | MODIFIED-RELEASE FORMULATIONS OF A BUPROPION SALT | SLC6A2, SLC6A3, SLC6A11 | SLC6A3 2/4885SLC6A2 1/4885CHRNA1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.